Found 2 bookmarks
Custom sorting
emClinical & Translational Immunology/em | ASI Journal | Wiley Online Library
emClinical & Translational Immunology/em | ASI Journal | Wiley Online Library
“In conclusion, our findings demonstrate that immunomodulatory changes in both myeloid and lymphoid cells can persist for up to 17 months following COVID-19, even in individuals who experienced only MILD illness.”m
#Immune system#Post-Acute Conditions#Myeloid cells#Lymphoid cells#immunomodulatory changes#Immune Deficiency#immune dysregulation#risks
·onlinelibrary.wiley.com·
emClinical & Translational Immunology/em | ASI Journal | Wiley Online Library
According to a NEW study, post COVID–19 patients showed immune dysregulation regardless of disease severity characterized mainly by altered expression of activation and functional markers in myeloid (CD39, CD64, CD85d, CD11b) and lymphoid cells (CD39, CD57, TIGIT). 1/
According to a NEW study, post COVID–19 patients showed immune dysregulation regardless of disease severity characterized mainly by altered expression of activation and functional markers in myeloid (CD39, CD64, CD85d, CD11b) and lymphoid cells (CD39, CD57, TIGIT). 1/
“According to a NEW study, post COVID–19 patients showed immune dysregulation regardless of disease severity characterized mainly by altered expression of activation and functional markers in myeloid (CD39, CD64, CD85d, CD11b) and lymphoid cells (CD39, CD57, TIGIT)”
#Immune system#Post-Acute Conditions#T-cells#Myeloid cells#Lymphoid cells#Immune dysregulation#Discussion#analysis
·x.com·
According to a NEW study, post COVID–19 patients showed immune dysregulation regardless of disease severity characterized mainly by altered expression of activation and functional markers in myeloid (CD39, CD64, CD85d, CD11b) and lymphoid cells (CD39, CD57, TIGIT). 1/